UBS AM
CTKB icon

UBS AM’s Cytek Biosciences CTKB Stock Holding History

UBS AM’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.54K Sell
582
-250
-30% -$1.18K ﹤0.01% 3558
2025
Q4 		$4.2K Buy
+832
New +$3.86K ﹤0.01% 3009
2025
Q3 		– Sell
-284,350
Closed -$967K – 2360
2025
Q2 		$967K Buy
284,350
+92,726
+48% +$309K ﹤0.01% 2393
2025
Q1 		$768K Sell
191,624
-5,434
-3% -$28.2K ﹤0.01% 2404
2024
Q4 		$1.28M Buy
197,058
+22,433
+13% +$134K ﹤0.01% 2261
2024
Q3 		$967K Sell
174,625
-24,528
-12% -$139K ﹤0.01% 2413
2024
Q2 		$1.11M Buy
199,153
+75,022
+60% +$451K ﹤0.01% 2323
2024
Q1 		$833K Buy
124,131
+1,015
+0.8% +$8.03K ﹤0.01% 2099
2023
Q4 		$1.12M Buy
123,116
+11,593
+10% +$73K ﹤0.01% 1964
2023
Q3 		$616K Buy
111,523
+47,428
+74% +$380K ﹤0.01% 2204
2023
Q2 		$589K Hold
64,095
– – ﹤0.01% 2254
2023
Q1 		$589K Buy
64,095
+1,063
+2% +$11.4K ﹤0.01% 2254
2022
Q4 		$644K Sell
63,032
-6,790
-10% -$91.3K ﹤0.01% 2068
2022
Q3 		$1.03M Buy
69,822
+5,865
+9% +$76.2K ﹤0.01% 1954
2022
Q2 		$686K Buy
+63,957
New +$637K ﹤0.01% 2156

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS AM's CTKB Position: Q1 2026 in Review

UBS AM reduced its Cytek Biosciences (CTKB) stake by 30% in Q1 2026, selling an estimated $1.18K and leaving 582 shares worth $2.54K. The position accounts for ﹤0.01% of the portfolio, ranked #3558.

UBS AM first reported a position in CTKB in Q2 2022 and has held it in 15 quarters since. The position peaked at $1.28M in Q4 2024. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • UBS AM held 582 shares of Cytek Biosciences worth $2.54K as of Q1 2026.
  • UBS AM sold 250 Cytek Biosciences shares in Q1 2026, an estimated $1.18K.
  • Cytek Biosciences made up ﹤0.01% of UBS AM's portfolio in Q1 2026, its #3558 holding.
  • UBS AM first reported a position in Cytek Biosciences in Q2 2022 and has held it in 15 quarters since.
  • UBS AM's Cytek Biosciences position peaked at $1.28M in Q4 2024.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.